🌏 台灣生技新創的另類突圍：從藥物研發挑戰到 AI 驅動的科研工具
- 前半段為文章的英文版本 (The first half is the English version)
- 後半段為中文版本 (The second half is the Mandarin version)
===
Taiwan’s Biotech Startups: A Distinct Path Beyond Drug Development
When people think of biotech innovation, the first thing that comes to mind is often new drug development. But the reality is sobering: bringing a single drug to market typically requires more than 10 years of R&D, billions of dollars in funding, and a regulatory pathway filled with complex clinical trials. For a market like Taiwan, with limited resources, this road is long and difficult, and true success stories have been rare.
Instead of competing in this capital-intensive marathon, Taiwanese startups are leveraging the island’s strengths in information and communication technology (ICT), precision manufacturing, and artificial intelligence (AI) to chart a different path in biotech.
The results are starting to show. Taiwan is not just producing drugs, but rather building world-class research tools and AI-driven medical platforms—solutions with shorter development cycles, faster commercialization, and international demand.
Case 1: Syncell — Taiwan’s First International Biotech Instrument Brand
In mid-2025, Syncell announced the completion of a Series A fundraising of NT$750 million (about USD 23 million).
The company focuses on advanced biotech instruments, specializing in protein localization and analysis—a foundation for understanding diseases at the molecular level. What sets Syncell apart is its ambition to become Taiwan’s first globally competitive high-end biotech instrument brand, a space traditionally dominated by U.S., European, and Japanese players.
By combining intellectual property, R&D capabilities, and Taiwan’s strengths in semiconductors and precision optics, Syncell is positioning itself at the intersection of biotech and deep tech.
Case 2: AIM — AI Medical Imaging Across Borders
Shortly before that, AIM (采風智匯) announced a Pre-A round of NT$125 million (about USD 3.8 million), co-led by WI Harper Group and BE Health Ventures, with participation from Cathay Venture and other strategic investors.
AIM develops AI-powered medical imaging solutions for early detection of chronic diseases such as cardiovascular conditions and osteoporosis. Its core products include:
- DeepPACS: A foundational AI imaging platform
- DeepXray: Bone and joint analysis, certified by both Taiwan’s TFDA and the U.S. FDA
- DeepSono: Echocardiography analysis, enabling faster detection of chronic heart failure
AIM’s solutions are already deployed in 50+ hospitals and clinics across Taiwan, while aggressively expanding into Japan, Vietnam, Thailand, and Malaysia. At Japan’s ITEM 2025 medical imaging expo, its DeepXray was awarded “Item of the Year” (2nd place) by medical media Rad Fan Plus, underscoring its international potential.
Taiwan’s Distinct Path in Biotech
These two cases highlight a clear trend: Taiwan’s biotech startups are sidestepping the high barriers of traditional drug development by focusing instead on research tools, medical devices, and AI platforms—solutions that play to Taiwan’s existing strengths.
- Shorter R&D cycles: Instruments and platforms can be commercialized far more quickly than drugs.
- Cross-border scalability: Medical imaging and research tools address global pain points and can easily expand into international markets.
- Synergy with Taiwan’s strengths: Precision manufacturing, optics, and AI software form the foundation for this new wave of biotech innovation.
Conclusion
For decades, Taiwan’s startup ecosystem has been defined by semiconductors, ICT, and software IT. But the recent fundraising successes of Syncell and AIM show that biotech is emerging as a third pillar in Taiwan’s innovation landscape.
Their cases prove that Taiwan can contribute to the world not only with chips and software, but also with AI-driven research tools and next-generation medical platforms.
This diversification not only enriches Taiwan’s startup ecosystem, but also demonstrates the power of cross-disciplinary innovation—finding unique positioning under constraints, and carving out a fresh path on the global biotech stage.
Further Reading
- Syncell Inc. Raises NT$750 Million in Series A Funding to Build Taiwan’s International-Class Biotech High-End Instrument Brand
- AIM has successfully closed our Pre-A round of funding
- Taiwan Startups Path to Unicorn: Overseas Expansion as an Inevitable Strategy
- Taiwan’s AI Cybersecurity Startup CyCraft Technology Secures Funding for Global Expansion
- Oen Tech Secures Series A Funding for Global Expansion
===
台灣生技新創的另類突圍：從藥物研發挑戰到 AI 驅動的科研工具
談到生技創新，許多人首先想到的往往是 新藥開發。然而現實卻是殘酷的：一款新藥從研發到上市，通常需要 超過 10 年的時間、動輒數十億美元的投入，以及繁瑣的臨床試驗與嚴格的法規審核。對於台灣這樣資源有限的市場來說，這條道路既漫長又艱難，真正成功的案例並不多。
但台灣的新創選擇了另一條路。與其在新藥這場資金與時間的長跑中競爭，台灣的新創團隊更善用自身在 資通訊（ICT）、精密製造，以及人工智慧 等方面的優勢，在生技領域開闢出獨特的突破口。
結果正在逐漸浮現。台灣的新創並非只專注於新藥，而是打造 世界級的科研工具與 AI 醫療平台 ——這些解決方案不僅縮短研發週期，更能快速走向國際市場，回應全球醫療的迫切需求。
案例一：新析生技 Syncell —— 打造台灣首個國際級生技儀器品牌
2025 年中，新析生技 Syncell 宣布完成 7.5 億元新台幣（約 2,300 萬美元）的 A 輪募資。
Syncell 的核心技術是高端科研儀器，專注於 蛋白質定位與分析，這是理解疾病機制的重要基礎。值得注意的是，Syncell 的目標並非僅限於本地市場，而是要打造 台灣第一個能在國際舞台上競爭的高端生技儀器品牌。
透過知識產權、研發能量，以及台灣在 半導體與光學精密製造 的強項，Syncell 正在站上生技與深科技（Deep Tech）交會的舞台。
案例二：采風智匯 AIM —— AI 醫療影像的跨境應用
不久之前，采風智匯 AIM 也宣布完成 Pre-A 輪募資 1.25 億元新台幣（約 380 萬美元），由美商中經合集團（WI Harper Group）與比翼生醫共同領投，國泰創投與永續影響力投資等策略夥伴亦參與其中。
AIM 的核心是 AI 醫療影像辨識，協助早期偵測心血管疾病與骨質疏鬆。旗下主要產品包括：
- DeepPACS：AI 影像基礎平台
- DeepXray：骨骼與關節檢測，已獲台灣 TFDA 與美國 FDA 認證
- DeepSono：心臟超音波分析，加速慢性心衰竭等疾病的診斷
目前 AIM 的解決方案已導入 超過 50 家台灣大型醫院與診所，並積極拓展 日本、越南、泰國、馬來西亞。在日本 ITEM 2025 醫療影像展中，AIM 的 DeepXray 更獲得專業醫學媒體 Rad Fan Plus 評選為 「2025 年度醫療器材」第二名，顯示其國際潛力。
台灣生技的獨特路徑
這兩個案例突顯出一個趨勢：台灣的新創正在避開傳統「新藥研發」的高門檻，轉而打造 科研工具、醫療器材與 AI 平台，並透過自身優勢快速走向國際。
- 研發週期更短：工具與平台的商業化速度明顯快於藥物。
- 跨境可擴展性：醫療影像與科研工具切中全球痛點，具備國際市場需求。
- 台灣優勢結合：半導體精密度、光學系統與軟體 AI，為生技創新奠定基礎。
結語
長久以來，台灣新創的代表性領域多半集中在 半導體、資通訊、與軟體 IT。然而近期 Syncell 與 AIM 的募資成功，說明生技領域也正成為台灣創業版圖中的 第三支柱。
他們的案例證明，台灣能夠貢獻給全球的不只是晶片與軟體，還有 AI 驅動的科研工具與新世代醫療平台。
這不僅讓台灣的新創生態系更加多元化，也展現了跨領域創新的力量：在有限資源下找到屬於自己的定位，並在全球生技舞台上闖出一條嶄新的道路。
One thought on “Taiwan’s Biotech Startups: A Distinct Path Beyond Drug Development”